sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
chloral hydrate
|
metronidazole
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p424
|
If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
|
sumatriptan
|
fluvoxamine
|
ADVISE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s17
|
DDI-DrugBank.d568.s17.p2
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
androgens
|
meclofenamic acid
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p25
|
In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.
|
levodopa
|
phenytoin
|
EFFECT
|
Carbidopa_ddi.xml
|
DDI-DrugBank.d47.s3
|
DDI-DrugBank.d47.s3.p0
|
Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.
|
Saquinavir
|
amprenavir
|
MECHANISM
|
Amprenavir_ddi.xml
|
DDI-DrugBank.d437.s7
|
DDI-DrugBank.d437.s7.p0
|
Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.
|
valdecoxib
|
ketoconazole
|
MECHANISM
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s29
|
DDI-DrugBank.d328.s29.p1
|
Aspirin: Animal studies wshow that aspirin given with nonsteroidal anti-inflammatory agents, including ibuprofen, yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.
|
aspirin
|
nonsteroidal anti-inflammatory agents
|
EFFECT
|
Ibuprofen_ddi.xml
|
DDI-DrugBank.d415.s2
|
DDI-DrugBank.d415.s2.p3
|
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
|
Agonist/antagonist analgesics
|
buprenorphine
|
NONE
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s6
|
DDI-DrugBank.d257.s6.p12
|
The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.
|
ergonovine
|
oxytocic drugs
|
EFFECT
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s12
|
DDI-DrugBank.d325.s12.p2
|
Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;
|
tricyclic
|
sympathomimetic agents
|
NONE
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s3
|
DDI-DrugBank.d158.s3.p6
|
Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.
|
nabumetone
|
warfarin
|
ADVISE
|
Nabumetone_ddi.xml
|
DDI-DrugBank.d174.s1
|
DDI-DrugBank.d174.s1.p0
|
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
|
VIRACEPT
|
Antiarrhythmics
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s6
|
DDI-DrugBank.d340.s6.p0
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
DURAGESIC
|
tranquilizers
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p17
|
Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.
|
phenytoin
|
bexarotene
|
MECHANISM
|
Bexarotene_ddi.xml
|
DDI-DrugBank.d467.s3
|
DDI-DrugBank.d467.s3.p4
|
Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.
|
PLETAL
|
ketoconazole
|
ADVISE
|
Cilostazol_ddi.xml
|
DDI-DrugBank.d358.s0
|
DDI-DrugBank.d358.s0.p4
|
DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.
|
DIAMOX
|
phenytoin
|
MECHANISM
|
Acetazolamide_ddi.xml
|
DDI-DrugBank.d368.s0
|
DDI-DrugBank.d368.s0.p1
|
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
|
IOPIDINE
|
barbiturates
|
ADVISE
|
Apraclonidine_ddi.xml
|
DDI-DrugBank.d224.s1
|
DDI-DrugBank.d224.s1.p2
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
contraceptives
|
vitamin D
|
NONE
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p71
|
Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of lisinopril may result in a further deterioration of renal function.
|
non-steroidal anti-inflammatory drugs
|
lisinopril
|
EFFECT
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s5
|
DDI-DrugBank.d334.s5.p2
|
Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
|
clozapine
|
flecainide
|
ADVISE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s30
|
DDI-DrugBank.d480.s30.p5
|
Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.
|
dapsone
|
Lamprene
|
EFFECT
|
Clofazimine_ddi.xml
|
DDI-DrugBank.d399.s0
|
DDI-DrugBank.d399.s0.p0
|
N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine.
|
N-methyllevallorphan
|
loperamide
|
EFFECT
|
7625885.xml
|
DDI-MedLine.d128.s15
|
DDI-MedLine.d128.s15.p0
|
With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions
|
dapsone
|
folic acid antagonists
|
EFFECT
|
Dapsone_ddi.xml
|
DDI-DrugBank.d185.s6
|
DDI-DrugBank.d185.s6.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
doxycycline
|
ziprasidone
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p598
|
Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.
|
Ketoconazole
|
tacrolimus
|
MECHANISM
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s10
|
DDI-DrugBank.d458.s10.p1
|
BREVIBLOC concentrations were equivocally higher when given with warfarin, but this is not likely to be clinically important.
|
BREVIBLOC
|
warfarin
|
MECHANISM
|
Esmolol_ddi.xml
|
DDI-DrugBank.d422.s3
|
DDI-DrugBank.d422.s3.p0
|
Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine.
|
warfarin
|
antipyrine
|
NONE
|
Famotidine_ddi.xml
|
DDI-DrugBank.d203.s2
|
DDI-DrugBank.d203.s2.p4
|
This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
|
NSAIDs
|
ACE inhibitors
|
ADVISE
|
Enalapril_ddi.xml
|
DDI-DrugBank.d107.s9
|
DDI-DrugBank.d107.s9.p0
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
Central Nervous System Depressants
|
tranquilizers
|
NONE
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p6
|
- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
|
non-steroidal anti-inflammatory agent
|
thiazide diuretics
|
EFFECT
|
Chlorothiazide_ddi.xml
|
DDI-DrugBank.d46.s19
|
DDI-DrugBank.d46.s19.p6
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Atromid-S
|
Sandimmune
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p692
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
lamotrigine
|
methadone
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p761
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
dicumarol
|
succinimides
|
NONE
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p122
|
Vasoconstrictors: D.H.E. 45 (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.
|
D.H.E. 45
|
peripheral vasoconstrictors
|
EFFECT
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s0
|
DDI-DrugBank.d410.s0.p4
|
Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
|
glimepiride
|
magnesium/choline salicylate
|
ADVISE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s1
|
DDI-DrugBank.d521.s1.p2
|
- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
|
Tindal
|
fluphenazine
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s21
|
DDI-DrugBank.d179.s21.p49
|
Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.
|
indinavir
|
efavirenz
|
MECHANISM
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s41
|
DDI-DrugBank.d97.s41.p2
|
Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.
|
Sonata
|
imipramine
|
EFFECT
|
Zaleplon_ddi.xml
|
DDI-DrugBank.d324.s4
|
DDI-DrugBank.d324.s4.p2
|
Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
|
felodipine
|
phenobarbital
|
MECHANISM
|
Felodipine_ddi.xml
|
DDI-DrugBank.d316.s14
|
DDI-DrugBank.d316.s14.p8
|
Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;
|
fluvoxamine maleate
|
alprazolam
|
MECHANISM
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s14
|
DDI-DrugBank.d76.s14.p4
|
Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
|
glimepiride
|
choline salicylate
|
ADVISE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s1
|
DDI-DrugBank.d521.s1.p6
|
If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.
|
dapsone
|
clofazimine
|
ADVISE
|
Clofazimine_ddi.xml
|
DDI-DrugBank.d399.s1
|
DDI-DrugBank.d399.s1.p0
|
The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers.
|
anesthetics
|
calcium channel blockers
|
EFFECT
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s22
|
DDI-DrugBank.d565.s22.p0
|
Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.
|
Buforin II
|
azithromycin
|
EFFECT
|
11152438.xml
|
DDI-MedLine.d47.s4
|
DDI-MedLine.d47.s4.p0
|
Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);
|
Zalcitabine
|
lamivudine
|
EFFECT
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s5
|
DDI-DrugBank.d263.s5.p0
|
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
|
saquinavir
|
budesonide
|
ADVISE
|
Budesonide_ddi.xml
|
DDI-DrugBank.d144.s1
|
DDI-DrugBank.d144.s1.p19
|
Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid.
|
vitamin B12
|
aminosalicylic acid
|
ADVISE
|
Aminosalicylic Acid_ddi.xml
|
DDI-DrugBank.d22.s3
|
DDI-DrugBank.d22.s3.p0
|
Theophylline: Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.
|
Grepafloxacin
|
theophylline
|
MECHANISM
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s6
|
DDI-DrugBank.d78.s6.p2
|
We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole.
|
CCNU
|
misonidazole
|
MECHANISM
|
3966974.xml
|
DDI-MedLine.d85.s14
|
DDI-MedLine.d85.s14.p0
|
In patients who have received muscle relaxants, doxapram may temporarily mask the residual effects of muscle relaxant drugs.
|
doxapram
|
muscle relaxant drugs
|
EFFECT
|
Doxapram_ddi.xml
|
DDI-DrugBank.d332.s1
|
DDI-DrugBank.d332.s1.p2
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
theophylline
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p41
|
It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.
|
enalapril
|
lithium
|
ADVISE
|
Enalapril_ddi.xml
|
DDI-DrugBank.d107.s17
|
DDI-DrugBank.d107.s17.p2
|
Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin;
|
Itraconazole
|
phenytoin
|
MECHANISM
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s20
|
DDI-DrugBank.d165.s20.p0
|
Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.
|
phenobarbital
|
felbamate
|
MECHANISM
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s33
|
DDI-DrugBank.d434.s33.p2
|
Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.
|
butorphanol
|
central nervous system depressants
|
EFFECT
|
Butorphanol_ddi.xml
|
DDI-DrugBank.d246.s0
|
DDI-DrugBank.d246.s0.p0
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
delavirdine
|
nicotinamide
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p171
|
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.
|
ALFENTA
|
opioids
|
EFFECT
|
Alfentanil_ddi.xml
|
DDI-DrugBank.d8.s0
|
DDI-DrugBank.d8.s0.p3
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
tacrolimus
|
triazolam
|
NONE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p98
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
hypnotics
|
skeletal muscle relaxants
|
NONE
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p61
|
There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.
|
nortriptyline
|
fluoxetine hydrochloride
|
MECHANISM
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s6
|
DDI-DrugBank.d202.s6.p2
|
Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
|
caffeine
|
phenytoin
|
ADVISE
|
Caffeine_ddi.xml
|
DDI-DrugBank.d89.s3
|
DDI-DrugBank.d89.s3.p24
|
Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.
|
alcohol
|
LEXAPRO
|
ADVISE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s1
|
DDI-DrugBank.d568.s1.p14
|
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
|
epinephrine
|
tricyclic antidepressants
|
EFFECT
|
Chloroprocaine_ddi.xml
|
DDI-DrugBank.d110.s0
|
DDI-DrugBank.d110.s0.p7
|
Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.
|
diazoxide
|
hydralazine
|
EFFECT
|
Hydralazine_ddi.xml
|
DDI-DrugBank.d31.s2
|
DDI-DrugBank.d31.s2.p0
|
An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate.
|
perchlorate
|
radiopertechnetate
|
NONE
|
163470.xml
|
DDI-MedLine.d134.s1
|
DDI-MedLine.d134.s1.p1
|
Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.
|
theophylline
|
fluvoxamine maleate
|
ADVISE
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s28
|
DDI-DrugBank.d76.s28.p0
|
Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.
|
Hypnotics
|
midazolam
|
NONE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s23
|
DDI-DrugBank.d124.s23.p4
|
CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus.
|
diltiazem
|
sirolimus
|
MECHANISM
|
11180036.xml
|
DDI-MedLine.d86.s8
|
DDI-MedLine.d86.s8.p0
|
Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.
|
atorvastatin
|
norethindrone
|
MECHANISM
|
Atorvastatin_ddi.xml
|
DDI-DrugBank.d140.s10
|
DDI-DrugBank.d140.s10.p5
|
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).
|
Gleevec
|
HMG-CoA reductase inhibitors
|
MECHANISM
|
Imatinib_ddi.xml
|
DDI-DrugBank.d115.s10
|
DDI-DrugBank.d115.s10.p2
|
Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.
|
cholestyramine
|
resin
|
NONE
|
Cholestyramine_ddi.xml
|
DDI-DrugBank.d566.s2
|
DDI-DrugBank.d566.s2.p20
|
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
|
glucocorticoids
|
insulin
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s7
|
DDI-MedLine.d12.s7.p10
|
Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.
|
leucovorin
|
fluorouracil
|
EFFECT
|
Capecitabine_ddi.xml
|
DDI-DrugBank.d88.s6
|
DDI-DrugBank.d88.s6.p0
|
Chloral hydrate may cause an increased prothrombin response by displacing the anticoagulant from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction, thus leading to inter-patient variation in ultimate prothrombin effect.
|
Chloral hydrate
|
anticoagulant
|
MECHANISM
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s4
|
DDI-DrugBank.d64.s4.p0
|
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylurea
|
nonsteroidal anti-inflammatory agents
|
EFFECT
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s0
|
DDI-DrugBank.d245.s0.p0
|
Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
|
norfloxacin
|
zafirlukast
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s25
|
DDI-DrugBank.d558.s25.p69
|
Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
|
ketoconazole
|
phenobarbital
|
NONE
|
Caffeine_ddi.xml
|
DDI-DrugBank.d89.s3
|
DDI-DrugBank.d89.s3.p20
|
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
|
epinephrine
|
phenothiazines
|
EFFECT
|
Chloroprocaine_ddi.xml
|
DDI-DrugBank.d110.s0
|
DDI-DrugBank.d110.s0.p8
|
The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromonab-CD3.
|
mycophenolate mofetil
|
muromonab-CD3
|
NONE
|
Basiliximab_ddi.xml
|
DDI-DrugBank.d544.s5
|
DDI-DrugBank.d544.s5.p14
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
clonazepam
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p7
|
Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.
|
naproxen
|
aspirin
|
ADVISE
|
Naproxen_ddi.xml
|
DDI-DrugBank.d85.s6
|
DDI-DrugBank.d85.s6.p5
|
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
|
dextran
|
anticoagulants
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s90
|
DDI-DrugBank.d64.s90.p27
|
Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
|
Matulane
|
L-tryptophan
|
NONE
|
L-Tryptophan_ddi.xml
|
DDI-DrugBank.d63.s0
|
DDI-DrugBank.d63.s0.p55
|
Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently.
|
PROLEUKIN
|
interferon-alfa
|
EFFECT
|
Aldesleukin_ddi.xml
|
DDI-DrugBank.d114.s8
|
DDI-DrugBank.d114.s8.p0
|
Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
|
TARCEVA
|
indinavir
|
ADVISE
|
Erlotinib_ddi.xml
|
DDI-DrugBank.d456.s1
|
DDI-DrugBank.d456.s1.p3
|
Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.
|
psychotropic medications
|
LEXAPRO
|
ADVISE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s1
|
DDI-DrugBank.d568.s1.p13
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
alprazolam
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
aminosalicylic acid
|
chymotrypsin
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p165
|
Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
|
PRINIVIL
|
potassium-sparing diuretics
|
EFFECT
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s15
|
DDI-DrugBank.d334.s15.p0
|
Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.
|
neomycin
|
methotrexate
|
MECHANISM
|
Neomycin_ddi.xml
|
DDI-DrugBank.d330.s2
|
DDI-DrugBank.d330.s2.p2
|
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
|
erythromycin
|
terfenadine
|
INT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s8
|
DDI-DrugBank.d397.s8.p11
|
Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.
|
INSPRA
|
NSAIDs
|
ADVISE
|
Eplerenone_ddi.xml
|
DDI-DrugBank.d20.s12
|
DDI-DrugBank.d20.s12.p0
|
Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.
|
anileridine
|
anesthetics
|
ADVISE
|
Anileridine_ddi.xml
|
DDI-DrugBank.d215.s0
|
DDI-DrugBank.d215.s0.p3
|
Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
|
EQUETROTM
|
Clomipramine HCl
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s13
|
DDI-DrugBank.d94.s13.p5
|
Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.
|
Ethoxzolamide
|
procainamide
|
EFFECT
|
Ethoxzolamide_ddi.xml
|
DDI-DrugBank.d286.s0
|
DDI-DrugBank.d286.s0.p2
|
Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.
|
Immunosuppressive
|
amiodarone
|
NONE
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s20
|
DDI-DrugBank.d143.s20.p2
|
- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.
|
insulin
|
Bezalip
|
EFFECT
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s3
|
DDI-DrugBank.d291.s3.p3
|
Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.
|
tricyclic antidepressants
|
guanethidine
|
EFFECT
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s4
|
DDI-DrugBank.d238.s4.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
phenylbutazone
|
quinidine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1336
|
Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.
|
enoxacin
|
R-warfarin
|
MECHANISM
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s23
|
DDI-DrugBank.d395.s23.p7
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.